CVM - Ready For A Bounce?

I think this stock has found support around the $.28-$.30 range and looks poised to post a bounce from here. I could see a 30-50% possible bounce up to $.40 - $.45 a share if it can get passed the resistance at $.38.

This is a liquid stock with over $100k in daily volume. It 52 week high is over $1.00.

Multikine® is the Company’s flagship immunotherapy and is in Phase III trials, so there is also the longer term possibility. They recently did a capital raise at $.30 a share, as will almost all young bio-techs capital is of the essence. Considering CVM has phase III trials ongoing the company is at least progressing and closer to some results than other younger bio-tech companies.


CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.